These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 29319493

  • 1. Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus.
    Yang TH, Wu TH, Chang YL, Liao HT, Hsu CC, Tsai CY, Chou YC.
    Clin Nephrol; 2018 Apr; 89(4):277-285. PubMed ID: 29319493
    [Abstract] [Full Text] [Related]

  • 2. Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis.
    Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, Malek Mahdavi A, Gojazadeh M, Khabbazi A.
    Mod Rheumatol; 2018 May; 28(3):523-529. PubMed ID: 28753077
    [Abstract] [Full Text] [Related]

  • 3. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
    Aragon E, Resontoc LP, Chan YH, Lau YW, Tan PH, Loh HL, Ng KH, Yap HK.
    Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment outcomes in refractory lupus nephritis: Data from an observational study.
    Gururani S, Devarasetti PK, Uppin M, Rajasekhar L.
    Lupus; 2021 Oct; 30(11):1725-1731. PubMed ID: 34304627
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D, Rodrigues M, da Silva JAP, Inês L.
    Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study.
    Chen YM, Hung WT, Liao YW, Hsu CY, Hsieh TY, Chen HH, Hsieh CW, Lin CT, Lai KL, Tang KT, Tseng CW, Huang WN, Chen YH.
    Lupus; 2019 Apr; 28(5):658-666. PubMed ID: 30971165
    [Abstract] [Full Text] [Related]

  • 10. Rituximab as add-on therapy in patients with resistant lupus nephritis who have failed induction or maintenance therapy with other agents: A real-world experience from a single center in Mumbai.
    Yadav S, Balakrishnan C, Mangat G, Kothari J.
    Lupus; 2024 Jan; 33(1):88-95. PubMed ID: 38048588
    [Abstract] [Full Text] [Related]

  • 11. Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis.
    El-Sehemy MS, Al-Saaran AM, Baddour NM, Adam AG, Moez PE.
    Egypt J Immunol; 2006 Jan; 13(1):39-52. PubMed ID: 17974149
    [Abstract] [Full Text] [Related]

  • 12. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis.
    Aragon E, Chan YH, Ng KH, Lau YW, Tan PH, Yap HK.
    Lupus; 2010 Jul; 19(8):965-73. PubMed ID: 20581019
    [Abstract] [Full Text] [Related]

  • 13. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus.
    Buyon JP, Kim MY, Guerra MM, Lu S, Reeves E, Petri M, Laskin CA, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Salmon JE.
    Clin J Am Soc Nephrol; 2017 Jun 07; 12(6):940-946. PubMed ID: 28400421
    [Abstract] [Full Text] [Related]

  • 14. Morphological Indexes: Can They Predict Lupus Nephritis Outcomes? A Retrospective Study.
    Navarro D, Ferreira AC, Viana H, Carvalho F, Nolasco F.
    Acta Med Port; 2019 Oct 01; 32(10):635-640. PubMed ID: 31625875
    [Abstract] [Full Text] [Related]

  • 15. Cyclosporine A in treatment of membranous lupus nephropathy.
    Hu W, Liu Z, Shen S, Li S, Yao X, Chen H, Li L.
    Chin Med J (Engl); 2003 Dec 01; 116(12):1827-30. PubMed ID: 14687467
    [Abstract] [Full Text] [Related]

  • 16. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria.
    Kasitanon N, Boripatkosol P, Louthrenoo W.
    Int J Rheum Dis; 2018 Jan 01; 21(1):200-207. PubMed ID: 28901731
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB.
    Lancet; 2021 May 29; 397(10289):2070-2080. PubMed ID: 33971155
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB, Won S, Bae SC.
    Lupus; 2018 May 29; 27(6):1007-1011. PubMed ID: 29448881
    [Abstract] [Full Text] [Related]

  • 19. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
    Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.
    Arthritis Care Res (Hoboken); 2011 Mar 29; 63(3):351-7. PubMed ID: 21080348
    [Abstract] [Full Text] [Related]

  • 20. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.
    Tanaka H, Oki E, Tsuruga K, Yashiro T, Hanada I, Ito E.
    Clin Nephrol; 2009 Dec 29; 72(6):430-6. PubMed ID: 19954719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.